SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512179-11-00

Acronym

Lifetime

Enrollment

182

Registered

2024-10-10

Start date

2023-10-26

Completion date

Unknown

Last updated

2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes

Brief summary

The primary objective is to test if kidney damage as shown by albuminuria in patients with CKDstage G1A2/G2A2 and prediabetes can be improved by a treatment with the SGLT2 inhibitordapagliflozin (10mg/day) and lifestyle counselling compared to placebo and lifestyle counsellingfor one year

Interventions

DRUGPlacebo matching Dapagliflozin

DRUGDAPAGLIFLOZIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary objective is to test if kidney damage as shown by albuminuria in patients with CKDstage G1A2/G2A2 and prediabetes can be improved by a treatment with the SGLT2 inhibitordapagliflozin (10mg/day) and lifestyle counselling compared to placebo and lifestyle counsellingfor one year	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026